Determinants of initiation and progression of idiopathic pulmonary fibrosis

Respirology

Volumn 14, Issue 7, 2009, Pages 917-933

  Kottmann, Robert Matthew ^a   Hogan, Christopher M ^a   Phipps, Richard P ^a   Sime, Patricia J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Cytokines; Genetics; Idiopathic pulmonary fibrosis; Initiation; Myofibroblasts; Progression

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIOXIDANT; AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; PIRFENIDONE; PREDNISONE; SOMATOMEDIN; SURFACTANT PROTEIN C; TRANSFORMING GROWTH FACTOR BETA;

CIGARETTE SMOKING; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DIABETES MELLITUS; DISEASE COURSE; DISEASE PREDISPOSITION; ENVIRONMENTAL EXPOSURE; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; MYOFIBROBLAST; NONHUMAN; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; VIRUS INFECTION;

AUTOIMMUNITY; CYTOKINES; DISEASE PROGRESSION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MUTATION; PULMONARY SURFACTANT-ASSOCIATED PROTEIN C; VIRUS DISEASES;

EID: 70049114954     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2009.01624.x     Document Type: Review

References (218)

1. Tsukamoto K, Hayakawa H, Sato A, Chida K, Nakamura H, Miura K. Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax 2000 55 (11 958 961.
2. Kelly BG, Lok SS, Hasleton PS, Egan JJ, Stewart JP. A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2002 166 (4 510 513.
3. Milstone AP, Brumble LM, Loyd JE, Ely EW, Roberts JR, Pierson RN, 3rd. et al. Active CMV infection before lung transplantation: risk factors and clinical implications. J. Heart Lung Transplant. 2000 19 (8 744 750.
4. Dworniczak S, Ziora D, Kapral M, Mazurek U, Niepsuj G, Rauer R et al. Human cytomegalovirus DNA level in patients with idiopathic pulmonary fibrosis. J. Physiol. Pharmacol. 2004 55 (Suppl. 3 67 75.
5. Yonemaru M, Kasuga I, Kusumoto H, Kunisawa A, Kiyokawa H, Kuwabara S et al. Elevation of antibodies to cytomegalovirus and other herpes viruses in pulmonary fibrosis. Eur. Respir. J. 1997 10 (9 2040 2045.
6. Tang YW, Johnson JE, Browning PJ, Cruz-Gervis RA, Davis A, Graham BS et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Microbiol. 2003 41 (6 2633 2640.
7. Ueda T, Ohta K, Suzuki N, Yamaguchi M, Hirai K, Horiuchi T et al. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am. Rev. Respir. Dis. 1992 146 (1 266 268.
8. Meliconi R, Andreone P, Fasano L, Galli S, Pacilli A, Miniero R et al. Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis. Thorax 1996 51 (3 315 317.
9. Irving WL, Day S, Johnston ID. Idiopathic pulmonary fibrosis and hepatitis C virus infection. Am. Rev. Respir. Dis. 1993 148 (6 Pt 1 1683 1684.
10. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y et al. Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis. World J. Gastroenterol. 2008 14 (38 5880 5886.
11. Bando M, Ohno S, Oshikawa K, Takahashi M, Okamoto H, Sugiyama Y. Infection of TT virus in patients with idiopathic pulmonary fibrosis. Respir. Med. 2001 95 (12 935 942. (Pubitemid 34013540)
12. Kuwano K, Kawasaki M, Kunitake R, Hagimoto N, Nomoto Y, Matsuba T et al. Detection of group C adenovirus DNA in small-cell lung cancer with the nested polymerase chain reaction. J. Cancer Res. Clin. Oncol. 1997 123 (7 377 382. (Pubitemid 27322103)
13. Hodgson U, Pulkkinen V, Dixon M, Peyrard-Janvid M, Rehn M, Lahermo P et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am. J. Hum. Genet. 2006 79 (1 149 154.
14. Grutters JC, du Bois RM. Genetics of fibrosing lung diseases. Eur. Respir. J. 2005 25 (5 915 927.
15. Nogee LM, Dunbar AE, 3rd., Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N. Engl. J. Med. 2001 344 (8 573 579.
16. Allam JS, Limper AH. Idiopathic pulmonary fibrosis: is it a familial disease? Curr. Opin. Pulm. Med. 2006 12 (5 312 317.
17. Checa M, Ruiz V, Montano M, Velazquez-Cruz R, Selman M, Pardo A. MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. Hum. Genet. 2008 124 (5 465 472.
18. Zorzetto M, Bombieri C, Ferrarotti I, Medaglia S, Agostini C, Tinelli C et al. Complement receptor 1 gene polymorphisms in sarcoidosis. Am. J. Respir. Cell Mol. Biol. 2002 27 (1 17 23.
19. Zorzetto M, Ferrarotti I, Trisolini R, Agli LL, Scabini R, Novo M et al. Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003 168 (3 330 334.
20. Sanders YY, Kumbla P, Hagood JS. Enhanced myofibroblastic differentiation and survival in Thy-1(-) lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 2007 36 (2 226 235.
21. Sanders YY, Pardo A, Selman M, Nuovo GJ, Tollefsbol TO, Siegal GP et al. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2008 39 (5 610 618.
22. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2007 356 (13 1317 1326.
23. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc. Natl. Acad. Sci. U.S.A. 2007 104 (18 7552 7557.
24. Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc. Natl. Acad. Sci. U.S.A. 2008 105 (35 13051 13056.
25. Behera D, Kaur S, Sathyanarayana G, Majumdar S. Surfactant protein-A in lung lavage fluid obtained from patients with idiopathic pulmonary fibrosis. J. Assoc. Physicians India 2002 50 : 1409 1412.
26. Greene KE, King TE, Jr., Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur. Respir. J. 2002 19 (3 439 446.
27. Selman M, Lin HM, Montano M, Jenkins AL, Estrada A, Lin Z et al. Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum. Genet. 2003 113 (6 542 550.
28. Agostini C, Gurrieri C. Chemokine/cytockine cocktail in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. 2006 3 (4 357 363.
29. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 2007 132 (4 1311 1321.
30. Krein PM, Winston BW. Roles for insulin-like growth factor I and transforming growth factor-beta in fibrotic lung disease. Chest 2002 122 (6 Suppl.) 289S 93S.
31. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest. 1997 100 (4 768 776.
32. Sporn MB, Roberts AB. Transforming growth factor-beta: recent progress and new challenges. J. Cell Biol. 1992 119 (5 1017 1021.
33. Yamada M, Kuwano K, Maeyama T, Yoshimi M, Hamada N, Fukumoto J et al. Gene transfer of soluble transforming growth factor type II receptor by in vivo electroporation attenuates lung injury and fibrosis. J. Clin. Pathol. 2007 60 (8 916 920.
34. Kolb M, Margetts PJ, Sime PJ, Gauldie J. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am. J. Physiol. Lung Cell Mol. Physiol. 2001 280 (6 L1327 34.
35. Kolb M, Margetts PJ, Galt T, Sime PJ, Xing Z, Schmidt M et al. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am. J. Respir. Crit. Care Med. 2001 163 (3 Pt 1 770 777.
36. Wang Q, Wang Y, Hyde DM, Gotwals PJ, Koteliansky VE, Ryan ST et al. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax 1999 54 (9 805 812.
37. Ferguson HE, Kulkarni A, Lehmann GM, Garcia-Bates TM, Thatcher TH, Huxlin KR et al. Electrophilic peroxisome proliferator activated receptor-{gamma} (PPAR{gamma}) ligands have potent anti-fibrotic effects in human lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 2009.
38. Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnet M et al. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 2005 288 (6 L1146 53.
39. Murray LA, Argentieri RL, Farrell FX, Bracht M, Sheng H, Whitaker B et al. Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2. Int. J. Biochem. Cell Biol. 2008 40 (10 2174 2182.
40. Kim JH, Jang YS, Eom KS, Hwang YI, Kang HR, Jang SH et al. Transforming growth factor beta1 induces epithelial-to-mesenchymal transition of A549 cells. J. Korean Med. Sci. 2007 22 (5 898 904.
41. Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am. J. Physiol. Lung Cell Mol. Physiol. 2007 293 (3 L525 34.
42. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir. Res. 2005 6 : 56.
43. Ramos C, Montano M, Garcia-Alvarez J, Ruiz V, Uhal BD, Selman M et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am. J. Respir. Cell Mol. Biol. 2001 24 (5 591 598.
44. Meloni F, Caporali R, Marone Bianco A, Paschetto E, Morosini M, Fietta AM et al. BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2004 21 (2 111 118.
45. Khalil N, O'Connor RN, Flanders KC, Unruh H. TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. Am. J. Respir. Cell Mol. Biol. 1996 14 (2 131 138.
46. Gu L, Xu WB, Liu HR, Guo ZJ, Xu XX, Zhu YJ. Different cytokine profiles in usual interstitial pneumonia and nonspecific interstitial pneumonia Zhonghua Jie He He Hu Xi Za Zhi 2003 26 (6 350 353.
47. Bergeron A, Soler P, Kambouchner M, Loiseau P, Milleron B, Valeyre D et al. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. Eur. Respir. J. 2003 22 (1 69 76.
48. Homma S, Nagaoka I, Abe H, Takahashi K, Seyama K, Nukiwa T et al. Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung. Am. J. Respir. Crit. Care Med. 1995 152 (6 Pt 1 2084 2089.
49. Gillery P, Leperre A, Maquart FX, Borel JP. Insulin-like growth factor-I (IGF-I) stimulates protein synthesis and collagen gene expression in monolayer and lattice cultures of fibroblasts. J. Cell. Physiol. 1992 152 (2 389 396.
50. Goldstein RH, Poliks CF, Pilch PF, Smith BD, Fine A. Stimulation of collagen formation by insulin and insulin-like growth factor I in cultures of human lung fibroblasts. Endocrinology 1989 124 (2 964 970.
51. Hetzel M, Bachem M, Anders D, Trischler G, Faehling M. Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts. Lung 2005 183 (4 225 237.
52. Pilewski JM, Liu L, Henry AC, Knauer AV, Feghali-Bostwick CA. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am. J. Pathol. 2005 166 (2 399 407.
53. Aston C, Jagirdar J, Lee TC, Hur T, Hintz RL, Rom WN. Enhanced insulin-like growth factor molecules in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1995 151 (5 1597 1603.
54. Nagaoka I, Trapnell BC, Crystal RG. Upregulation of platelet-derived growth factor-A and -B gene expression in alveolar macrophages of individuals with idiopathic pulmonary fibrosis. J. Clin. Invest. 1990 85 (6 2023 2027.
55. Vignaud JM, Allam M, Martinet N, Pech M, Plenat F, Martinet Y. Presence of platelet-derived growth factor in normal and fibrotic lung is specifically associated with interstitial macrophages, while both interstitial macrophages and alveolar epithelial cells express the c-sis proto-oncogene. Am. J. Respir. Cell Mol. Biol. 1991 5 (6 531 538.
56. Mio T, Nagai S, Kitaichi M, Kawatani A, Izumi T. Proliferative characteristics of fibroblast lines derived from open lung biopsy specimens of patients with IPF (UIP). Chest 1992 102 (3 832 837.
57. Cao B, Guo Z, Xu W, Zhu Y The potential role of cytokine expression and its relation to angiogenesis in idiopathic pulmonary fibrosis Zhonghua Nei Ke Za Zhi 1999 38 (12 814 816.
58. Lasky JA, Ortiz LA, Tonthat B, Hoyle GW, Corti M, Athas G et al. Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am. J. Physiol. 1998 275 (2 Pt 1 L365 71.
59. Pan LH, Yamauchi K, Uzuki M, Nakanishi T, Takigawa M, Inoue H et al. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur. Respir. J. 2001 17 (6 1220 1227.
60. Grotendorst GR. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 1997 8 (3 171 179.
61. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J. 1999 13 (13 1774 1786.
62. Kelly M, Kolb M, Bonniaud P, Gauldie J. Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr. Pharm. Des. 2003 9 (1 39 49.
63. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J. Clin. Invest. 2001 107 (12 1529 1536.
64. Kline JN, Schwartz DA, Monick MM, Floerchinger CS, Hunninghake GW. Relative release of interleukin-1 beta and interleukin-1 receptor antagonist by alveolar macrophages. A study in asbestos-induced lung disease, sarcoidosis, and idiopathic pulmonary fibrosis. Chest 1993 104 (1 47 53.
65. Freeburn RW, Armstrong L, Millar AB. Cultured alveolar macrophages from patients with idiopathic pulmonary fibrosis (IPF) show dysregulation of lipopolysaccharide-induced tumor necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10) inductions. Eur. Cytokine Netw. 2005 16 (1 5 16.
66. Johnston CJ, Piedboeuf B, Rubin P, Williams JP, Baggs R, Finkelstein JN. Early and persistent alterations in the expression of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor alpha mRNA levels in fibrosis-resistant and sensitive mice after thoracic irradiation. Radiat. Res. 1996 145 (6 762 767.
67. Thrall RS, Vogel SN, Evans R, Shultz LD. Role of tumor necrosis factor-alpha in the spontaneous development of pulmonary fibrosis in viable motheaten mutant mice. Am. J. Pathol. 1997 151 (5 1303 1310.
68. Ortiz LA, Lasky J, Hamilton RF, Jr., Holian A, Hoyle GW, Banks W et al. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp. Lung Res. 1998 24 (6 721 743.
69. Miyazaki Y, Araki K, Vesin C, Garcia I, Kapanci Y, Whitsett JA et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J. Clin. Invest. 1995 96 (1 250 259.
70. Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, Graham FL et al. Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. Am. J. Pathol. 1998 153 (3 825 832.
71. Liu JY, Brass DM, Hoyle GW, Brody AR. TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am. J. Pathol. 1998 153 (6 1839 1847.
72. Eickelberg O, Pansky A, Mussmann R, Bihl M, Tamm M, Hildebrand P et al. Transforming growth factor-beta1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts. J. Biol. Chem. 1999 274 (18 12933 12938.
73. DiCosmo BF, Geba GP, Picarella D, Elias JA, Rankin JA, Stripp BR et al. Airway epithelial cell expression of interleukin-6 in transgenic mice. Uncoupling of airway inflammation and bronchial hyperreactivity. J. Clin. Invest. 1994 94 (5 2028 2035.
74. Moodley YP, Misso NL, Scaffidi AK, Fogel-Petrovic M, McAnulty RJ, Laurent GJ et al. Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am. J. Respir. Cell Mol. Biol. 2003 29 (4 490 498.
75. Elias JA, Zheng T, Whiting NL, Trow TK, Merrill WW, Zitnik R et al. IL-1 and transforming growth factor-beta regulation of fibroblast-derived IL-11. J. Immunol. 1994 152 (5 2421 2429.
76. Tang W, Geba GP, Zheng T, Ray P, Homer RJ, Kuhn C, 3rd. et al. Targeted expression of IL-11 in the murine airway causes lymphocytic inflammation, bronchial remodeling, and airways obstruction. J. Clin. Invest. 1996 98 (12 2845 2853.
77. Ray P, Tang W, Wang P, Homer R, Kuhn C, 3rd., Flavell RA et al. Regulated overexpression of interleukin 11 in the lung. Use to dissociate development-dependent and -independent phenotypes. J. Clin. Invest. 1997 100 (10 2501 2511.
78. Ziegenhagen MW, Zabel P, Zissel G, Schlaak M, Muller-Quernheim J. Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am. J. Respir. Crit. Care Med. 1998 157 (3 Pt 1 762 768.
79. Car BD, Meloni F, Luisetti M, Semenzato G, Gialdroni-Grassi G, Walz A. Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 1994 149 (3 Pt 1 655 659.
80. Carre PC, Mortenson RL, King TE, Jr., Noble PW, Sable CL, Riches DW. Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. J. Clin. Invest. 1991 88 (6 1802 1810.
81. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 1996 17 (3 138 146.
82. Furuie H, Yamasaki H, Suga M, Ando M. Altered accessory cell function of alveolar macrophages: a possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. Eur. Respir. J. 1997 10 (4 787 794. (Pubitemid 27180188)
83. Capelli A, Di Stefano A, Gnemmi I, Donner CF. CCR5 expression and CC chemokine levels in idiopathic pulmonary fibrosis. Eur. Respir. J. 2005 25 (4 701 707.
84. Baran CP, Opalek JM, McMaken S, Newland CA, O'Brien JM, Jr., Hunter MG et al. Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2007 176 (1 78 89.
85. Elias JA, Rossman MD, Zurier RB, Daniele RP. Human alveolar macrophage inhibition of lung fibroblast growth. A prostaglandin-dependent process. Am. Rev. Respir. Dis. 1985 131 (1 94 9.
86. Saltzman LE, Moss J, Berg RA, Hom B, Crystal RG. Modulation of collagen production by fibroblasts. Effects of chronic exposure to agonists that increase intracellular cyclic AMP. Biochem. J. 1982 204 (1 25 30.
87. Fine A, Poliks CF, Donahue LP, Smith BD, Goldstein RH. The differential effect of prostaglandin E2 on transforming growth factor-beta and insulin-induced collagen formation in lung fibroblasts. J. Biol. Chem. 1989 264 (29 16988 16991.
88. Kolodsick JE, Peters-Golden M, Larios J, Toews GB, Thannickal VJ, Moore BB. Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am. J. Respir. Cell Mol. Biol. 2003 29 (5 537 544.
89. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters-Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J. Clin. Invest. 1995 95 (4 1861 1868.
90. Keerthisingam CB, Jenkins RG, Harrison NK, Hernandez-Rodriguez NA, Booth H, Laurent GJ et al. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am. J. Pathol. 2001 158 (4 1411 1422.
91. Hodges RJ, Jenkins RG, Wheeler-Jones CP, Copeman DM, Bottoms SE, Bellingan GJ et al. Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) production. Am. J. Pathol. 2004 165 (5 1663 1676.
92. Jenkins G, Hart SL, Hodges RJ, Meng QH, Kinnon C, Laurent GJ et al. Cyclooxygenase-2 overexpression, using an integrin-targeted gene delivery system (the LID vector), inhibits fibroblast proliferation in vitro and leads to increased prostaglandin E(2) in the lung. Chest 2002 121 (3 Suppl. 102S 104S.
93. Li JZ, Li ZH, Kang J, Hou XM, Yu RJ Change of prostaglandin E2 and interleukin-12, interleukin-13 in the bronchoalveolar lavage fluid and the serum of the patients with idiopathic pulmonary fibrosis Zhonghua Jie He He Hu Xi Za Zhi 2004 27 (6 378 380.
94. Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, Wright TM, Curran-Everett D, West SG et al. Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J. Rheumatol. 2006 33 (8 1600 1605.
95. Baumgartner U, Scholmerich J, Becher S, Costabel U. Detection of antibodies in serum of patients with idiopathic pulmonary fibrosis against isolated rat alveolar type II cells. Respiration 1987 52 (2 122 128.
96. Yang Y, Fujita J, Bandoh S, Ohtsuki Y, Yamadori I, Yoshinouchi T et al. Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. Clin. Exp. Immunol. 2002 128 (1 169 174.
97. Dobashi N, Fujita J, Murota M, Ohtsuki Y, Yamadori I, Yoshinouchi T et al. Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. Lung 2000 178 (3 171 179.
98. Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T et al. Elevated serum and BAL cytokeratin 19 fragment in pulmonary fibrosis and acute interstitial pneumonia. Eur. Respir. J. 1999 14 (3 574 578.
99. Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T et al. Circulating cytokeratin 8: anti-cytokeratin 8 antibody immune complexes in sera of patients with pulmonary fibrosis. Respiration 2000 67 (4 397 401.
100. Nakos G, Adams A, Andriopoulos N. Antibodies to collagen in patients with idiopathic pulmonary fibrosis. Chest 1993 103 (4 1051 1058.
101. Cantin AM, Boileau R, Begin R. Increased procollagen III aminoterminal peptide-related antigens and fibroblast growth signals in the lungs of patients with idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 1988 137 (3 572 578.
102. Meliconi R, Negri C, Borzi RM, Facchini A, Sturani C, Fasano L et al. Antibodies to topoisomerase II in idiopathic pulmonary fibrosis. Clin. Rheumatol. 1993 12 (3 311 315.
103. Grigolo B, Mazzetti I, Borzi RM, Hickson ID, Fabbri M, Fasano L et al. Mapping of topoisomerase II alpha epitopes recognized by autoantibodies in idiopathic pulmonary fibrosis. Clin. Exp. Immunol. 1998 114 (3 339 346.
104. Nozaki Y, Liu T, Hatano K, Gharaee-Kermani M, Phan SH. Induction of telomerase activity in fibroblasts from bleomycin-injured lungs. Am. J. Respir. Cell Mol. Biol. 2000 23 (4 460 465.
105. Liu T, Nozaki Y, Phan SH. Regulation of telomerase activity in rat lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 2002 26 (5 534 540.
106. Liu T, Chung MJ, Ullenbruch M, Yu H, Jin H, Hu B et al. Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice. J. Clin. Invest. 2007 117 (12 3800 3809.
107. Magro CM, Allen J, Pope-Harman A, Waldman WJ, Moh P, Rothrauff S et al. The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am. J. Clin. Pathol. 2003 119 (4 556 567.
108. Ogushi F, Tani K, Endo T, Tada H, Kawano T, Asano T et al. Autoantibodies to IL-1 alpha in sera from rapidly progressive idiopathic pulmonary fibrosis. J. Med. Invest. 2001 48 (3-4 181 189.
109. Oshikawa K, Sugiyama Y. Serum anti-p53 autoantibodies from patients with idiopathic pulmonary fibrosis associated with lung cancer. Respir. Med. 2000 94 (11 1085 1091.
110. Takahashi T, Wada I, Ohtsuka Y, Munakata M, Homma Y, Kuroki Y. Autoantibody to alanyl-tRNA synthetase in patients with idiopathic pulmonary fibrosis. Respirology 2007 12 (5 642 653.
111. Lambre CR, Pilatte Y, Le Maho S, Greffard A, De Cremoux H, Bignon J. Sialidase activity and antibodies to sialidase-treated autologous erythrocytes in bronchoalveolar lavages from patients with idiopathic pulmonary fibrosis or sarcoidosis. Clin. Exp. Immunol. 1988 73 (2 230 235.
112. Hashimoto N, Jin H, Liu T, Chensue SW, Phan SH. Bone marrow-derived progenitor cells in pulmonary fibrosis. J. Clin. Invest. 2004 113 (2 243 252.
113. Dunsmore SE, Shapiro SD. The bone marrow leaves its scar: new concepts in pulmonary fibrosis. J. Clin. Invest. 2004 113 (2 180 182.
114. Gharaee-Kermani M, Gyetko MR, Hu B, Phan SH. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. Pharm. Res. 2007 24 (5 819 841.
115. Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002 122 (6 Suppl. 286S 289S.
116. Phan SH, Zhang K, Zhang HY, Gharaee-Kermani M. The myofibroblast as an inflammatory cell in pulmonary fibrosis. Curr. Top. Pathol. 1999 93 : 173 182.
117. Phan SH. Role of the myofibroblast in pulmonary fibrosis. Kidney Int. Suppl. 1996 54 : S46 8.
118. Willis BC, duBois RM, Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc. Am. Thorac. Soc. 2006 3 (4 377 382.
119. Keeley EC, Mehrad B, Strieter RM. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of fibrotic disorders. Thromb. Haemost. 2009 101 (4 613 618.
120. Epperly MW, Guo H, Gretton JE, Greenberger JS. Bone marrow origin of myofibroblasts in irradiation pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2003 29 (2 213 224.
121. Gomer RH. Circulating progenitor cells and scleroderma. Curr. Rheumatol. Rep. 2008 10 (3 183 188.
122. Pilling D, Buckley CD, Salmon M, Gomer RH. Inhibition of fibrocyte differentiation by serum amyloid P. J. Immunol. 2003 171 (10 5537 5546.
123. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J. Immunol. 2003 171 (1 380 389.
124. Saunders R, Siddiqui S, Kaur D, Doe C, Sutcliffe A, Hollins F et al. Fibrocyte localization to the airway smooth muscle is a feature of asthma. J. Allergy Clin. Immunol. 2009 123 (2 376 384.
125. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol. 2001 166 (12 7556 7562.
126. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1994 1 (1 71 81.
127. Chesney J, Metz C, Stavitsky AB, Bacher M, Bucala R. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J. Immunol. 1998 160 (1 419 425.
128. Metz CN. Fibrocytes: a unique cell population implicated in wound healing. Cell. Mol. Life Sci. 2003 60 (7 1342 1350.
129. Abe S, Boyer C, Liu X, Wen FQ, Kobayashi T, Fang Q et al. Cells derived from the circulation contribute to the repair of lung injury. Am. J. Respir. Crit. Care Med. 2004 170 (11 1158 1163.
130. Andersson-Sjoland A, de Alba CG, Nihlberg K, Becerril C, Ramirez R, Pardo A et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int. J. Biochem. Cell Biol. 2008 40 (10 2129 2140.
131. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am. J. Pathol. 2005 166 (3 675 684.
132. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest. 2004 114 (3 438 446.
133. Xu J, Gonzalez ET, Iyer SS, Mac V, Mora AL, Sutliff RL et al. Use of senescence-accelerated mouse model in bleomycin-induced lung injury suggests that bone marrow-derived cells can alter the outcome of lung injury in aged mice. J. Gerontol. A Biol. Sci. Med. Sci. 2009 64 : 731 739.
134. Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc. Am. Thorac. Soc. 2006 3 (4 293 298.
135. Antoniou KM, Hansell DM, Rubens MB, Marten K, Desai SR, Siafakas NM et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am. J. Respir. Crit. Care Med. 2008 177 (2 190 194.
136. de Cremoux H, Bernaudin JF, Laurent P, Brochard P, Bignon J. Interactions between cigarette smoking and the natural history of idiopathic pulmonary fibrosis. Chest 1990 98 (1 71 6.
137. Enomoto T, Usuki J, Azuma A, Nakagawa T, Kudoh S. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest 2003 123 (6 2007 2011.
138. Baumgartner KB, Samet JM, Coultas DB, Stidley CA, Hunt WC, Colby TV et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. Am. J. Epidemiol. 2000 152 (4 307 315.
139. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1997 155 (1 242 248.
140. Iwai K, Mori T, Yamada N, Yamaguchi M, Hosoda Y. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am. J. Respir. Crit. Care Med. 1994 150 (3 670 675.
141. Taskar V, Coultas D. Exposures and idiopathic lung disease. Semin. Respir. Crit. Care Med. 2008 29 (6 670 679.
142. Lenz AG, Costabel U, Maier KL. Oxidized BAL fluid proteins in patients with interstitial lung diseases. Eur. Respir. J. 1996 9 (2 307 312.
143. Steppling H, Nagel M, Strausz J, Muller-Quernheim J Increased oxidative metabolism of alveolar macrophages in idiopathic fibrosing alveolitis Pneumologie 1990 44 (Suppl. 1 303 305.
144. Strausz J, Muller-Quernheim J, Steppling H, Ferlinz R. Oxygen radical production by alveolar inflammatory cells in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 1990 141 (1 124 128.
145. Wilborn J, Bailie M, Coffey M, Burdick M, Strieter R, Peters-Golden M. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Invest. 1996 97 (8 1827 1836.
146. Kinnula VL, Hodgson UA, Lakari EK, Tan RJ, Sormunen RT, Soini YM et al. Extracellular superoxide dismutase has a highly specific localization in idiopathic pulmonary fibrosis/usual interstitial pneumonia. Histopathology 2006 49 (1 66 74.
147. Saleh D, Barnes PJ, Giaid A. Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1997 155 (5 1763 1769.
148. Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 1989 139 (2 370 372.
149. Cantin AM, North SL, Hubbard RC, Crystal RG. Normal alveolar epithelial lining fluid contains high levels of glutathione. J. Appl. Physiol. 1987 63 (1 152 157.
150. Beeh KM, Beier J, Haas IC, Kornmann O, Micke P, Buhl R. Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2002 19 (6 1119 1123.
151. Cantin AM, Larivee P, Begin RO. Extracellular glutathione suppresses human lung fibroblast proliferation. Am. J. Respir. Cell Mol. Biol. 1990 3 (1 79 85.
152. Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ. 1990 301 (6759 1015 1017.
153. Mannino DM, Etzel RA, Parrish RG. Pulmonary fibrosis deaths in the United States, 1979-1991. An analysis of multiple-cause mortality data. Am. J. Respir. Crit. Care Med. 1996 153 (5 1548 1552.
154. King TE, Jr., Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med. 2001 164 (7 1171 1181.
155. Patti MG, Tedesco P, Golden J, Hays S, Hoopes C, Meneghetti A et al. Idiopathic pulmonary fibrosis: how often is it really idiopathic? J. Gastrointest. Surg. 2005 9 (8 1053 1056 discussion 1056 1058.
156. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur. Respir. J. 2006 27 (1 136 142.
157. Tobin RW, Pope CE, 2nd., Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998 158 (6 1804 1808.
158. Hubbard RB, Smith C, Le Jeune I, Gribbin J, Fogarty AW. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am. J. Respir. Crit. Care Med. 2008 178 (12 1257 1261.
159. Hubbard R, Venn A, Smith C, Cooper M, Johnston I, Britton J. Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study. Am. J. Respir. Crit. Care Med. 1998 157 (3 Pt 1 743 747.
160. Hubbard R, Venn A, Britton J. Exposure to antidepressants and the risk of cryptogenic fibrosing alveolitis: a case-control study. Eur. Respir. J. 2000 16 (3 409 413. (Pubitemid 30739234)
161. Mapel DW, Hunt WC, Utton R, Baumgartner KB, Samet JM, Coultas DB. Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax 1998 53 (6 469 476.
162. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE, Jr. et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann. Intern. Med. 2005 142 (12 Pt 1 963 967.
163. Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest 1997 111 (1 51 7.
164. Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2002 166 (2 173 177.
165. King TE, Jr., Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA, Jr. et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am. J. Respir. Crit. Care Med. 2001 164 (6 1025 1032.
166. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur. Respir. J. 2006 27 (1 143 150.
167. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005 171 (9 1040 1047.
168. Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am. J. Roentgenol. 1997 168 (1 79 83.
169. Akira M, Kozuka T, Yamamoto S, Sakatani M. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008 178 (4 372 378.
170. Hamada H, Sakatani M, Nishioka M, Akira M, Yamamoto S, Ueda E High levels of elastolytic activity in bronchoalveolar lavage fluid from a patient with idiopathic interstitial pneumonia Nihon Kyobu Shikkan Gakkai Zasshi 1997 35 (11 1238 1244.
171. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?. Eur. Respir. J. 2007 30 (5 835 839.
172. Hiwatari N, Shimura S, Takishima T, Shirato K. Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients. Tohoku J. Exp. Med. 1994 174 (4 379 386.
173. Suga T, Sugiyama Y, Ohno S, Kitamura S Two cases of IIP which developed acute exacerbation after bronchoalveolar lavage Nihon Kyobu Shikkan Gakkai Zasshi 1994 32 (2 174 178.
174. Tasaka S, Kanazawa M, Komune Y, Soejima K, Hirakata M, Yamaguchi K et al. Acute exacerbation of subacute interstitial pneumonia after thoracoscopic lung biopsy Nihon Kokyuki Gakkai Zasshi 1998 36 (2 182 186.
175. Kondoh Y, Taniguchi H, Kitaichi M, Yokoi T, Johkoh T, Oishi T et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir. Med. 2006 100 (10 1753 1759.
176. Enomoto T, Kawamoto M, Kunugi S, Hiramatsu K, Sakakibara K, Usuki J et al. Clinicopathological analysis of patients with idiopathic pulmonary fibrosis which became acutely exacerbated after video-assisted thoracoscopic surgical lung biopsy Nihon Kokyuki Gakkai Zasshi 2002 40 (10 806 811.
177. Yuksel M, Ozyurtkan MO, Bostanci K, Ahiskali R, Kodalli N. Acute exacerbation of interstitial fibrosis after pulmonary resection. Ann. Thorac. Surg. 2006 82 (1 336 338.
178. Kumar P, Goldstraw P, Yamada K, Nicholson AG, Wells AU, Hansell DM et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J. Thorac. Cardiovasc. Surg. 2003 125 (6 1321 1327.
179. Hoshikawa Y, Kondo T Perioperative lung injury: acute exacerbation of idiopathic pulmonary fibrosis and acute interstitial pneumonia after pulmonary resection Nippon Geka Gakkai Zasshi 2004 105 (12 757 762.
180. Zheng L, Zhou Z, Lin L, Alber S, Watkins S, Kaminski N et al. Carbon monoxide modulates {alpha}-smooth muscle actin and small proline rich-1a expression in fibrosis. Am. J. Respir. Cell Mol. Biol. 2009 41 : 85 92.
181. Olson AL, Swigris JJ, Raghu G, Brown KK. Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter. Chest 2009 136 : 16 22.
182. Malizia AP, Keating DT, Smith SM, Walls D, Doran PP, Egan JJ. Alveolar epithelial cell injury with Epstein-Barr virus upregulates TGFbeta1 expression. Am. J. Physiol. Lung Cell Mol. Physiol. 2008 295 (3 L451 60.
183. Lok SS, Stewart JP, Kelly BG, Hasleton PS, Egan JJ. Epstein-Barr virus and wild p53 in idiopathic pulmonary fibrosis. Respir. Med. 2001 95 (10 787 791.
184. Bando M, Takahashi M, Ohno S, Hosono T, Hironaka M, Okamoto H et al. Torque teno virus DNA titre elevated in idiopathic pulmonary fibrosis with primary lung cancer. Respirology 2008 13 (2 263 269.
185. Hayashi S, Hogg JC. Adenovirus infections and lung disease. Curr. Opin. Pharmacol. 2007 7 (3 237 243.
186. Vasakova M, Sterclova M, Kolesar L, Slavcev A, Pohunek P, Sulc J et al. Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. Scand. J. Immunol. 2009 69 (3 268 274.
187. Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009 179 (8 717 723.
188. Knight DA, Ernst M, Anderson GP, Moodley YP, Mutsaers SE. The role of gp130/IL-6 cytokines in the development of pulmonary fibrosis: critical determinants of disease susceptibility and progression? Pharmacol. Ther. 2003 99 (3 327 338.
189. White ES, Lazar MH, Thannickal VJ. Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis. J Pathol. 2003 201 (3 343 354.
190. Ziegenhagen MW, Schrum S, Zissel G, Zipfel PF, Schlaak M, Muller-Quernheim J. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J. Investig. Med. 1998 46 (5 223 231.
191. McCormack FX, King TE, Jr., Bucher BL, Nielsen L, Mason RJ. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1995 152 (2 751 759.
192. Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am. J. Respir. Crit. Care Med. 2000 162 (3 Pt 1 1109 1114.
193. Panos RJ, Bak PM, Simonet WS, Rubin JS, Smith LJ. Intratracheal instillation of keratinocyte growth factor decreases hyperoxia-induced mortality in rats. J. Clin. Invest. 1995 96 (4 2026 2033.
194. Yano T, Mason RJ, Pan T, Deterding RR, Nielsen LD, Shannon JM. KGF regulates pulmonary epithelial proliferation and surfactant protein gene expression in adult rat lung. Am. J. Physiol. Lung Cell Mol. Physiol. 2000 279 (6 L1146 58.
195. Yano T, Deterding RR, Simonet WS, Shannon JM, Mason RJ. Keratinocyte growth factor reduces lung damage due to acid instillation in rats. Am. J. Respir. Cell Mol. Biol. 1996 15 (4 433 442.
196. Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 2006 173 (2 188 198.
197. Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS ONE 2007 2 (5 e482.
198. Boon K, Bailey NW, Yang J, Steel MP, Groshong S, Kervitsky D et al. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS ONE 2009 4 (4 e5134.
199. Vasakova M, Striz I, Dutka J, Slavcev A, Jandova S, Kolesar L et al. Cytokine gene polymorphisms and high-resolution-computed tomography score in idiopathic pulmonary fibrosis. Respir. Med. 2007 101 (5 944 950. (Pubitemid 46508680)
200. Kurosu K, Takiguchi Y, Okada O, Yumoto N, Sakao S, Tada Y et al. Identification of annexin 1 as a novel autoantigen in acute exacerbation of idiopathic pulmonary fibrosis. J. Immunol. 2008 181 (1 756 767.
201. Mehrad B, Burdick MD, Strieter RM. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int. J. Biochem. Cell Biol. 2009 41 (8-9 1708 1718.
202. Mehrad B, Burdick MD, Zisman DA, Keane MP, Belperio JA, Strieter RM. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun. 2007 353 (1 104 108.
203. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009 179 (7 588 594.
204. Meyer A, Buhl R, Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur. Respir. J. 1994 7 (3 431 436.
205. Buhl R, Vogelmeier C, Critenden M, Hubbard RC, Hoyt RF, Jr., Wilson EM et al. Augmentation of glutathione in the fluid lining the epithelium of the lower respiratory tract by directly administering glutathione aerosol. Proc. Natl. Acad. Sci. U.S.A. 1990 87 (11 4063 4067.
206. Meyer A, Buhl R, Kampf S, Magnussen H. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am. J. Respir. Crit. Care Med. 1995 152 (3 1055 1060.
207. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005 353 (21 2229 2242.
208. Pereira CA, Malheiros T, Coletta EM, Ferreira RG, Rubin AS, Otta JS et al. Survival in idiopathic pulmonary fibrosis-cytotoxic agents compared to corticosteroids. Respir. Med. 2006 100 (2 340 347.
209. Fiorucci E, Lucantoni G, Paone G, Zotti M, Li BE, Serpilli M et al. Colchicine, cyclophosphamide and prednisone in the treatment of mild-moderate idiopathic pulmonary fibrosis: comparison of three currently available therapeutic regimens. Eur. Rev. Med. Pharmacol. Sci. 2008 12 (2 105 111.
210. Collard HR, Ryu JH, Douglas WW, Schwarz MI, Curran-Everett D, King TE, Jr. et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004 125 (6 2169 2174.
211. Grgic A, Lausberg H, Heinrich M, Koenig J, Uder M, Sybrecht GW et al. Progression of fibrosis in usual interstitial pneumonia: serial evaluation of the native lung after single lung transplantation. Respiration 2008 76 (2 139 145.
212. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. 1991 144 (2 291 296.
213. King TE, Jr., Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008 177 (1 75 81.
214. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 1999 341 (17 1264 1269.
215. King TE, Jr. Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. N. Engl. J. Med. 2000 342 (13 974 975.
216. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2004 350 (2 125 133. (Pubitemid 38056223)
217. Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006 129 (3 794 800.
218. Prasse A, Müller-Quernheim J. Noninvasive biomarkers in pulmonary fibrosis. Respirology 2009 14 : 788 795.